Literature DB >> 26677039

Analysis of corneal esthesia in patients undergoing photorefractive keratectomy.

Elmar Torres Neto1, Lucas Marcel Amaral Silva1, Giovana Arlene Fioravanti Lui1, Rachel Lopes Rodrigues Gomes2, Adamo Lui-Netto1.   

Abstract

PURPOSE: To quantitatively analyze corneal esthesia in patients undergoing photorefractive keratectomy (PRK) surgery.
METHODS: Forty-five patients selected for PRK in one eye underwent corneal esthesia using a Cochet-Bonnet esthesiometer preoperatively and 30 and 90 days postoperatively. Patients with a refractive diopter error of 4 or greater received intraoperative 0.02% mitomycin C for 20 s.
RESULTS: Twenty-four (53.3%) of the 45 eyes received intraoperative 0.02% mitomycin. Decreased sensitivity was observed on postoperative day 30. By postoperative day 90, corneal esthesia had normalized but remained 14.9% lower than preoperative levels. In the mitomycin group, no recovery of corneal esthesia to normal sensitivity levels was observed. The mean esthesiometer level was 39.2 mm on postoperative day 90 (P<0.001).
CONCLUSIONS: The results of the present study demonstrate recovery of corneal esthesia to normal levels at 90 days postoperatively in patients who did not receive mitomycin C. In patients administered mitomycin C, a 23.59% reduction in the corneal touch threshold was observed compared with preoperative levels indicating a failure of recovery to normal levels.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26677039     DOI: 10.5935/0004-2749.20150096

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  2 in total

1.  Outcomes of photorefractive keratectomy in patients with atypical topography.

Authors:  Hossein Movahedan; Ehsan Namvar; Mohsen Farvardin
Journal:  Electron Physician       Date:  2017-11-25

2.  Evaluation of corneal sensitivity in multiple sclerosis patients.

Authors:  Georges Sukkarieh; Ralph Ghorayeb; Mohamad Issa; Salam Koussa; Naji Waked
Journal:  Indian J Ophthalmol       Date:  2021-09       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.